Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBITDA (2022 - 2025)

Historic EBITDA for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$38.0 million.

  • Stoke Therapeutics' EBITDA fell 4475.6% to -$38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.8 million, marking a year-over-year increase of 13884.86%. This contributed to the annual value of -$89.1 million for FY2024, which is 1394.52% up from last year.
  • Per Stoke Therapeutics' latest filing, its EBITDA stood at -$38.0 million for Q3 2025, which was down 4475.6% from -$23.3 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' EBITDA peaked at $112.9 million during Q1 2025, and registered a low of -$38.0 million during Q3 2025.
  • Over the past 4 years, Stoke Therapeutics' median EBITDA value was -$25.2 million (recorded in 2022), while the average stood at -$16.2 million.
  • Over the last 5 years, Stoke Therapeutics' EBITDA had its largest YoY gain of 52856.17% in 2025, and its largest YoY loss of 4475.6% in 2025.
  • Over the past 4 years, Stoke Therapeutics' EBITDA (Quarter) stood at -$25.1 million in 2022, then fell by 6.8% to -$26.8 million in 2023, then soared by 59.76% to -$10.8 million in 2024, then crashed by 251.86% to -$38.0 million in 2025.
  • Its EBITDA stands at -$38.0 million for Q3 2025, versus -$23.3 million for Q2 2025 and $112.9 million for Q1 2025.